Sanofi Pasteur, the vaccines division of Sanofi, has launched its paediatric pentavalent vaccine, ‘Shan5’, developed and manufactured by its affiliate Shantha in India. The vaccine is a fully-liquid five-in-one, convenient, safe and high-quality vaccine that provides efficient protection for children from 6 weeks against five diseases: diphtheria, tetanus,pertussis, Hib and hepatitis B.

The launch of ‘Shan5’ vaccine acquired prequalification status from the World Health Organization (WHO) last April. Shan5’s prequalification gives many more children in India access to the latest high- quality, fully-liquid, 5-in-1 vaccine. Further, the prequalification helps Shan5 secure the supply of pentavalent combination vaccines in over 50 low-income countries. It adds to the current list of four vaccines that Shantha manufactures that includes Shanchol-the innovative cholera vaccine.

Click Here To Read More